Generics

Innovative Products found!

Biosimilars

Medical devices

Nutraceuticals

Filters

Pp-045 manufacturers

Filters

1 products found

pp-045

Solution for infusion

Dossier type
CTD
Dossier status
Under development
Country of origin
South Korea
Comments
Indication: Solid tumors with ERBB3 (HER3) pathway involvement; evaluated in advanced/metastatic cancers. Clinical stage: Phase 1 ( in the USA). Modality: Biologic (humanized monoclonal antibody). Mechanism / Target: Anti-ERBB3 (HER3) IgG1 mAb, designed to block neuregulin-ERBB3 signaling that drives tumor growth, survival, and resistance to EGFR/ERBB-targeted therapies. Route / form: Intravenous infusion. Differentiation: Targets HER3—a validated resistance node in EGFR, HER2, and PI3K-driven cancers—making it a complementary candidate for combination development.
Manufacturer #16907

This South Korea–based life-sciences organization develops a portfolio of small-molecule and biologic therapeutics, with a strategic focus on oncology, immunology, and metabolic diseases. Its pharmaceutical R&D is supported by global clinical programs and collaborations aimed at advancing first-in-class and best-in-class candidates. The group also maintains established therapeutic franchises and leverages international partnerships to expand its presence in the global healthcare market.

Want to see all products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription

Interested in Subscription?

Please fill out form and send us your specific requirements, and we will get back to you as soon as possible

Want unlimited access to the Pipelinepharma database?

Become a subscriber to unlock:

  • Streamlined product sourcing: access the only CTD dossier pipeline and sourcing platform.

  • Direct connections: communicate directly with CTD dossier owners and manufacturers with no brokerage fees.

  • Higher profitability: compare multiple supplier offers and secure the best commercial terms.

  • Expanded network: view supplier portfolios and stay updated on new products.

  • Value-added product ideas: discover products with lower competition potential.

  • Access to marketing authorizations for sale: find already registered products in your target markets.